^
MET amplification
GastroEsophageal Cancer
crizotinib
Sensitive
:
C3
Target Oncol - 3wk
HER-2 positive
GastroEsophageal Cancer
trastuzumab
Sensitive
:
A2
PD-L1 overexpression
GastroEsophageal Cancer
PD1 inhibitor
Sensitive
:
B
PD-L1 overexpression
GastroEsophageal Cancer
PD-L1 inhibitor
Sensitive
:
B
PD-L1 expression
GastroEsophageal Cancer
pembrolizumab
Sensitive
:
C1
HER-2 positive
GastroEsophageal Cancer
pembrolizumab
Sensitive
:
C2
TP53 mutation
GastroEsophageal Cancer
Immunotherapy
Resistant
:
C3
TET1 mutation
GastroEsophageal Cancer
Immunotherapy
Sensitive
:
C3
HER-2 expression
GastroEsophageal Cancer
ZW25
Sensitive
:
C3
PD-L1 expression
GastroEsophageal Cancer
Immunotherapy
Sensitive
:
C3
HER-2 overexpression
GastroEsophageal Cancer
RC48
Sensitive
:
C3
PD-L1 expression
GastroEsophageal Cancer
tislelizumab
Sensitive
:
C3
FGFR2 amplification
GastroEsophageal Cancer
ABSK-091
Sensitive
:
C3
TGFB1 elevation
GastroEsophageal Cancer
M7824
Sensitive
:
C3
HER-2 positive
GastroEsophageal Cancer
pembrolizumab + trastuzumab
Sensitive
:
C3
HER-2 overexpression
GastroEsophageal Cancer
ZW25
Sensitive
:
C3
MET amplification
GastroEsophageal Cancer
afatinib
Resistant
:
C3
EGFR amplification + ERBB2 amplification
GastroEsophageal Cancer
afatinib
Sensitive
:
C3
CFB overexpression
GastroEsophageal Cancer
sunitinib
Sensitive
:
C3
VEGFC-H
GastroEsophageal Cancer
sunitinib
Sensitive
:
C3
HER-2 positive
GastroEsophageal Cancer
pembrolizumab + margetuximab
Sensitive
:
C3
HER-2 mutation
GastroEsophageal Cancer
dasatinib
Sensitive
:
D
HER-2 mutation
GastroEsophageal Cancer
neratinib
Sensitive
:
D
HER-2 mutation
GastroEsophageal Cancer
dasatinib + neratinib
Sensitive
:
D
BCL2 overexpression + MCL1 overexpression
GastroEsophageal Cancer
AT 101
Sensitive
:
D
VERI is free for non-commercial use, no login needed.
Content on this site is for research purposes only and is not intended  to be a substitute for medical advice.
For commercial access, including additional premium features, please contact us.
By using VERI, you are agreeing to our